← Organon & overview

Organon & vs Amneal Pharmaceuticals, Inc. Class A Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Organon & Co (OGN)

Q2 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

June 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Latest
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Q3 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

August 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Latest
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.